CoChat

The Anti-Inflammatory Drug Leflunomide Is an Agonist of the Aryl Hydrocarbon Receptor

Open access

The DOI matches its Crossref record; 46 of the 46 references it cites were found in a registry or an index.

Abstract

BACKGROUND: The aryl hydrocarbon receptor (AhR) is a ligand-activated transcription factor that mediates the toxicity and biological activity of dioxins and related chemicals. The AhR influences a variety of processes involved in cellular growth and differentiation, and recent studies have suggested that the AhR is a potential target for immune-mediated diseases. METHODOLOGY/PRINCIPAL FINDINGS: During a screen for molecules that activate the AhR, leflunomide, an immunomodulatory drug presently used in the clinic for the treatment of rheumatoid arthritis, was identified as an AhR agonist. We aimed to determine whether any biological activity of leflunomide could be attributed to a previously unappreciated interaction with the AhR. The currently established mechanism of action of leflunomide involves its metabolism to A771726, possibly by cytochrome P450 enzymes, followed by inhibition of de novo pyrimidine biosynthesis by A771726. Our results demonstrate that leflunomide, but not its metabolite A771726, caused nuclear translocation of AhR into the nucleus and increased expression of AhR-responsive reporter genes and endogenous AhR target genes in an AhR-dependent manner. In silico Molecular Docking studies employing AhR ligand binding domain revealed favorable binding energy for leflunomide, but not for A771726. Further, leflunomide, but not A771726, inhibited in vivo epimorphic regeneration in a zebrafish model of tissue regeneration in an AhR-dependent manner. However, suppression of lymphocyte proliferation by leflunomide or A771726 was not dependent on AhR. CONCLUSIONS: These data reveal that leflunomide, an anti-inflammatory drug, is an agonist of the AhR. Our findings link AhR activation by leflunomide to inhibition of fin regeneration in zebrafish. Identification of alternative AhR agonists is a critical step in evaluating the AhR as a therapeutic target for the treatment of immune disorders.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1371/journal.pone.0013128

Cites

46 of 46 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1 Induction of AhR-mediated reporter gene activity by leflunomide. (A) Hepa1.1 cells were treated with varying doses of leflunomide ranging from 0.3 to 30 µM for 4 hours and luciferase activity was measured. Treatment with 1 nM TCDD was included as a positive control. Leflunomide strongly induced the luciferase reporter gene starting from 1 µM. (B) WT mouse Hepa1 hepatoma or human HepG2 hepatoma cells (C) were transiently transfected with an XRE-Luc reporter gene and β-galactosidase expression vector as described in the methods section. Cells were treated with leflunomide or TCDD as indicated for 16 hours and assayed for luciferase activity; Luciferase values are normalized to β-galactosidase activity. In both WT Hepa1 and HepG2 cells, treatment with 10, 5, or 1 µM significantly increased reporter gene activity, although to a lesser extent than 1 nM TCDD. (D) HepG2 cells were co-transfected with an Arnt expression vector (300 ng) along with the XRE-Luc reporter gene (600 ng). A significant increase in the XRE reporter gene activity was observed compared to HEPG2 cells transfected with the XRE reporter construct alone. Results are the mean ± SEM of at least three independent experiments. *** p<0.0001, ** p<0.001, * p<0.05 as determined by ANOVA with a Newman-Keuls multiple comparison post-test.
Figure 1 Induction of AhR-mediated reporter gene activity by leflunomide. (A) Hepa1.1 cells were treated with varying doses of leflunomide ranging from 0.3 to 30 µM for 4 hours and luciferase activity was measured. Treatment with 1 nM TCDD was included as a positive control. Leflunomide strongly induced the luciferase reporter gene starting from 1 µM. (B) WT mouse Hepa1 hepatoma or human HepG2 hepatoma cells (C) were transiently transfected with an XRE-Luc reporter gene and β-galactosidase expression vector as described in the methods section. Cells were treated with leflunomide or TCDD as indicated for 16 hours and assayed for luciferase activity; Luciferase values are normalized to β-galactosidase activity. In both WT Hepa1 and HepG2 cells, treatment with 10, 5, or 1 µM significantly increased reporter gene activity, although to a lesser extent than 1 nM TCDD. (D) HepG2 cells were co-transfected with an Arnt expression vector (300 ng) along with the XRE-Luc reporter gene (600 ng). A significant increase in the XRE reporter gene activity was observed compared to HEPG2 cells transfected with the XRE reporter construct alone. Results are the mean ± SEM of at least three independent experiments. *** p<0.0001, ** p<0.001, * p<0.05 as determined by ANOVA with a Newman-Keuls multiple comparison post-test.CC BY · PubMed Central
Figure 2 Activation of the AhR target genes by leflunomide. Hepa1 and HepG2 cells were treated with vehicle (V, 0.1% DMSO), TCDD (T, 1 nM), or leflunomide (L20, 20 µM; L10, 10 µM; L1, 1 µM) for 18 hours. RNA was isolated and semi quantitative RT-PCR was performed for the AhR target genes Cytochrome P450 1A1 (CYP1A1), Cytochrome P450 1A2 (CYP1A2), UDP glucuronosyltransferase 1A1 (UGT1A1), and NAD(P)H dehydrogenase [quinone 1] (NQO1), as described in the methods section. Expression analysis of GAPDH (Glyceraldehyde-3-phosphate dehydrogenase) was performed as a control. Cycle numbers during which PCR reactions were sampled are indicated. PCR products were visualized on a 2% TAE agarose gel stained with ethidium bromide. Leflunomide activated the selected panel of AhR target genes in WT Hepa1 (A) and HepG2 cells (B).
Figure 2 Activation of the AhR target genes by leflunomide. Hepa1 and HepG2 cells were treated with vehicle (V, 0.1% DMSO), TCDD (T, 1 nM), or leflunomide (L20, 20 µM; L10, 10 µM; L1, 1 µM) for 18 hours. RNA was isolated and semi quantitative RT-PCR was performed for the AhR target genes Cytochrome P450 1A1 (CYP1A1), Cytochrome P450 1A2 (CYP1A2), UDP glucuronosyltransferase 1A1 (UGT1A1), and NAD(P)H dehydrogenase [quinone 1] (NQO1), as described in the methods section. Expression analysis of GAPDH (Glyceraldehyde-3-phosphate dehydrogenase) was performed as a control. Cycle numbers during which PCR reactions were sampled are indicated. PCR products were visualized on a 2% TAE agarose gel stained with ethidium bromide. Leflunomide activated the selected panel of AhR target genes in WT Hepa1 (A) and HepG2 cells (B).CC BY · PubMed Central
Figure 3 Activation of AhR target genes by leflunomide requires Arnt. (A) Induction of the AhR target genes CYP1A1, UGT1A1, and NQO1 was performed as in figure 2. Vehicle (V, 0.1% DMSO), TCDD (T, 1 nM), leflunomide (L20, 20 µM; L10, 10 µM). GAPDH expression was used as a control. PCR cycle numbers are indicated. Target gene induction in Hepa1 vT{2} cells expressing a functional Arnt protein was similar as to that seen with WT Hepa1 cells. CYP1A1 and NQO1 were not induced by leflunomide in Hepa1 C4 cells that do not express a functional Arnt protein. (B–C) XRE-Luc reporter gene assays in Hepa1 vT{2} and C4 cells. Cells were transfected and treated with leflunomide or controls (VEH, Vehicle, 0.1% v/v DMSO; TCDD, 1 nM; and LEF, leflunomide,10 µM) as described in the methods section. (B) Consistent with semi quantitative RT-PCR analysis, TCDD and leflunomide induced expression of the XRE-Luc reporter gene in Hepa1 vT{2} cells. (C) Treatment with TCDD or leflunomide failed to activate the XRE-Luc reporter in the Hepa1 C4 cells. However, transient co-expression of Arnt rescued XRE-Luc reporter gene induction. Reporter gene assays are the mean ± SEM of three independent experiments.
Figure 3 Activation of AhR target genes by leflunomide requires Arnt. (A) Induction of the AhR target genes CYP1A1, UGT1A1, and NQO1 was performed as in figure 2. Vehicle (V, 0.1% DMSO), TCDD (T, 1 nM), leflunomide (L20, 20 µM; L10, 10 µM). GAPDH expression was used as a control. PCR cycle numbers are indicated. Target gene induction in Hepa1 vT{2} cells expressing a functional Arnt protein was similar as to that seen with WT Hepa1 cells. CYP1A1 and NQO1 were not induced by leflunomide in Hepa1 C4 cells that do not express a functional Arnt protein. (B–C) XRE-Luc reporter gene assays in Hepa1 vT{2} and C4 cells. Cells were transfected and treated with leflunomide or controls (VEH, Vehicle, 0.1% v/v DMSO; TCDD, 1 nM; and LEF, leflunomide,10 µM) as described in the methods section. (B) Consistent with semi quantitative RT-PCR analysis, TCDD and leflunomide induced expression of the XRE-Luc reporter gene in Hepa1 vT{2} cells. (C) Treatment with TCDD or leflunomide failed to activate the XRE-Luc reporter in the Hepa1 C4 cells. However, transient co-expression of Arnt rescued XRE-Luc reporter gene induction. Reporter gene assays are the mean ± SEM of three independent experiments.CC BY · PubMed Central
Figure 4 Leflunomide, but not its active metabolite, A771726, activates the AhR. (A) Structures of leflunomide (left) and its metabolite A771726 (right). (B–C) Reporter gene assays were conducted in Hepa1.1 cells or in HepG2 cells transiently transfected with XRE-Luc reporter gene. Results are the mean ± SEM of at least three independent experiments, each of which consisted of at least three biological replicates. ***: p<0.001 compared with vehicle treatment and p<0.05 compared with corresponding dose of A771726. (D) To confirm the observations of the reporter gene assays, we performed semi quantitative RT-PCR in WT Hepa1 cells for CYP1A1 with total RNA isolated from cells treated with vehicle (0.1% DMSO), leflunomide (L, 20 µM) or A771726 (M, 20 µM) as described in Figure 2. GAPDH was included as a control. Consistent with reporter gene assays, A771726 failed to activate CYP1A1 beyond that of vehicle treatment, while leflunomide induced strong CYP1A1 expression. (E) Cellular localization of AhR was analyzed by immunofluorescence of Hepa1 cells treated with TCDD, leflunomide, or A771726 for 1 or 3 hours. The FITC (green) channel represents AhR staining, while DAPI (blue) represents the nucleus. The AhR translocated to the nucleus following treatment with both TCDD and leflunomide, while it remained in the cytosol following treatment with A771726. (F) M2 is the major tautomeric form of A771726. Molecular docking of M2 and leflunomide in the homology models of mouse (G) and human (H) AhR ligand binding domain reveal favorable energetic and docking for leflunomide but not M2.
Figure 4 Leflunomide, but not its active metabolite, A771726, activates the AhR. (A) Structures of leflunomide (left) and its metabolite A771726 (right). (B–C) Reporter gene assays were conducted in Hepa1.1 cells or in HepG2 cells transiently transfected with XRE-Luc reporter gene. Results are the mean ± SEM of at least three independent experiments, each of which consisted of at least three biological replicates. ***: p<0.001 compared with vehicle treatment and p<0.05 compared with corresponding dose of A771726. (D) To confirm the observations of the reporter gene assays, we performed semi quantitative RT-PCR in WT Hepa1 cells for CYP1A1 with total RNA isolated from cells treated with vehicle (0.1% DMSO), leflunomide (L, 20 µM) or A771726 (M, 20 µM) as described in Figure 2. GAPDH was included as a control. Consistent with reporter gene assays, A771726 failed to activate CYP1A1 beyond that of vehicle treatment, while leflunomide induced strong CYP1A1 expression. (E) Cellular localization of AhR was analyzed by immunofluorescence of Hepa1 cells treated with TCDD, leflunomide, or A771726 for 1 or 3 hours. The FITC (green) channel represents AhR staining, while DAPI (blue) represents the nucleus. The AhR translocated to the nucleus following treatment with both TCDD and leflunomide, while it remained in the cytosol following treatment with A771726. (F) M2 is the major tautomeric form of A771726. Molecular docking of M2 and leflunomide in the homology models of mouse (G) and human (H) AhR ligand binding domain reveal favorable energetic and docking for leflunomide but not M2.CC BY · PubMed Central
Figure 5 Leflunomide induces aryl hydrocarbon receptor dependent expression of CYP1A1 in zebrafish. (A) One-cell stage wildtype embryos were injected with a control morpholino or AhR2 morpholino. At 6 hpf, the zebrafish were exposed to 10 µM leflunomide for 3 days. Immunohistochemistry for CYP1A, a known AhR2 target gene in zebrafish, demonstrated that leflunomide induces CYP1A expression in an AhR2 dependent manner. (B) Exposure of zebrafish to A771726 at doses of either 1 or 10 µM did not increase CYP1A expression.
Figure 5 Leflunomide induces aryl hydrocarbon receptor dependent expression of CYP1A1 in zebrafish. (A) One-cell stage wildtype embryos were injected with a control morpholino or AhR2 morpholino. At 6 hpf, the zebrafish were exposed to 10 µM leflunomide for 3 days. Immunohistochemistry for CYP1A, a known AhR2 target gene in zebrafish, demonstrated that leflunomide induces CYP1A expression in an AhR2 dependent manner. (B) Exposure of zebrafish to A771726 at doses of either 1 or 10 µM did not increase CYP1A expression.CC BY · PubMed Central
Figure 6 Leflunomide acts through the AhR to inhibit regeneration in an AhR-dependent manner. Amputation of the caudal zebrafish fin is a well-established model used to study tissue regeneration; TCDD is known to inhibit this regeneration process. To investigate whether leflunomide behaves like TCDD to inhibit epimorphic regeneration through the AhR, one-cell stage embryos were injected with a control or AhR2 morpholino, and the caudal fin was amputated at 48 hpf, followed by immediate exposure to vehicle or 25 µM leflunomide. (A) After 3 days, images of the fins were taken with brightfield microscopy. In addition, immunohistochemistry for CYP1A confirmed that leflunomide activated AhR2 (dotted line indicates the plane of amputation). (B) Although A771726 did not appear to activate the AhR in vivo or in our cell culture models, we investigated whether the compound could also inhibit fin regeneration, as inhibition of cell growth via disruption of de novo pyrimidine biosynthesis inhibition is a well-characterized endpoint of A771726. Amputated zebrafish were exposed to vehicle or 10 µM A771726. Exposure to 10 µM A771726 did not influence the regenerative process.
Figure 6 Leflunomide acts through the AhR to inhibit regeneration in an AhR-dependent manner. Amputation of the caudal zebrafish fin is a well-established model used to study tissue regeneration; TCDD is known to inhibit this regeneration process. To investigate whether leflunomide behaves like TCDD to inhibit epimorphic regeneration through the AhR, one-cell stage embryos were injected with a control or AhR2 morpholino, and the caudal fin was amputated at 48 hpf, followed by immediate exposure to vehicle or 25 µM leflunomide. (A) After 3 days, images of the fins were taken with brightfield microscopy. In addition, immunohistochemistry for CYP1A confirmed that leflunomide activated AhR2 (dotted line indicates the plane of amputation). (B) Although A771726 did not appear to activate the AhR in vivo or in our cell culture models, we investigated whether the compound could also inhibit fin regeneration, as inhibition of cell growth via disruption of de novo pyrimidine biosynthesis inhibition is a well-characterized endpoint of A771726. Amputated zebrafish were exposed to vehicle or 10 µM A771726. Exposure to 10 µM A771726 did not influence the regenerative process.CC BY · PubMed Central
Figure 7 The AhR is not required for the suppression of murine T-cell proliferation by leflunomide. Spleens of AhR +/+ and AhR −/− mice (A, Western blot) were removed and whole murine splenocytes were labeled with Carboxy-Fluoroscein-Diacetate Succinimidyl-Ester (CFSE) and stimulated to proliferate in vitro with anti-CD3 and LPS treatment in the absence or presence of vehicle and different doses of leflunomide or A771726. After 3 days, cells were harvested and stained for CD4 or CD8. (B) Viable cells were gated and CD4 and CD8 positive cell populations were then analyzed using single parameter (CFSE) histograms to evaluate cellular divisions based on CFSE staining. Cellular viability was not affected by either leflunomide or A771726 at the concentrations used. (C) Dose-dependent inhibition of cellular proliferation by leflunomide in CD4+ cells is not dependent upon the AhR. (D) Dose-dependent inhibition of cellular proliferation by leflunomide in CD8+ cells is not dependent upon the AhR. (E–F) A771726-induced inhibition of CD4+ or CD8+ proliferation is similar between AhR +/+ and AhR −/− cells. AhR −/− cells, black bars; AhR +/+ cells, white bars. Results are the mean from two independent experiments. Two-way ANOVA for both CD4+ and CD8+ assays did not reveal any statistically significant differences between cell divisions in AhR +/+ and AhR −/− cells whereas the effect of leflunomide on cell division compared to vehicle treatment was highly significant in both cases (p<0.0001).
Figure 7 The AhR is not required for the suppression of murine T-cell proliferation by leflunomide. Spleens of AhR +/+ and AhR −/− mice (A, Western blot) were removed and whole murine splenocytes were labeled with Carboxy-Fluoroscein-Diacetate Succinimidyl-Ester (CFSE) and stimulated to proliferate in vitro with anti-CD3 and LPS treatment in the absence or presence of vehicle and different doses of leflunomide or A771726. After 3 days, cells were harvested and stained for CD4 or CD8. (B) Viable cells were gated and CD4 and CD8 positive cell populations were then analyzed using single parameter (CFSE) histograms to evaluate cellular divisions based on CFSE staining. Cellular viability was not affected by either leflunomide or A771726 at the concentrations used. (C) Dose-dependent inhibition of cellular proliferation by leflunomide in CD4+ cells is not dependent upon the AhR. (D) Dose-dependent inhibition of cellular proliferation by leflunomide in CD8+ cells is not dependent upon the AhR. (E–F) A771726-induced inhibition of CD4+ or CD8+ proliferation is similar between AhR +/+ and AhR −/− cells. AhR −/− cells, black bars; AhR +/+ cells, white bars. Results are the mean from two independent experiments. Two-way ANOVA for both CD4+ and CD8+ assays did not reveal any statistically significant differences between cell divisions in AhR +/+ and AhR −/− cells whereas the effect of leflunomide on cell division compared to vehicle treatment was highly significant in both cases (p<0.0001).CC BY · PubMed Central
Figure 8 Inhibition of CYP1A2 by fluvoxamine increases AhR-mediated reporter gene activity. A) Identification of limiting doses of leflunomide capable of activating the AhR. Hepa1.1 cells were treated for 4 hours with varying doses of leflunomide in order to identify concentrations necessary for minimal activation of reporter gene activity. Leflunomide at 0.5 µM (dashed box) resulted in an approximately 2-fold induction of reporter gene and was selected for further analysis with the CYP1A2 inhibitor fluvoxamine. B) The CYP1A2 inhibitor fluvoxamine increases leflunomide-induced reporter gene activity in Hepa1.1 cells. Hepa1.1 cells were pre-treated with fluvoxamine for 3 hours and then dosed with 0.5 µM leflunomide for an additional 4 hours. Leflunomide-mediated reporter gene activity was enhanced by pre-treatment with fluvoxamine compared with vehicle treated cells and fluvoxamine-only treated cells. Results are the mean ± SEM of three independent experiments, each with at least three biological replicates. * p<0.05 relative to vehicle treatment, ** p<0.001 relative to both vehicle treatment and vehicle treated cells pre-treated with fluvoxamine.
Figure 8 Inhibition of CYP1A2 by fluvoxamine increases AhR-mediated reporter gene activity. A) Identification of limiting doses of leflunomide capable of activating the AhR. Hepa1.1 cells were treated for 4 hours with varying doses of leflunomide in order to identify concentrations necessary for minimal activation of reporter gene activity. Leflunomide at 0.5 µM (dashed box) resulted in an approximately 2-fold induction of reporter gene and was selected for further analysis with the CYP1A2 inhibitor fluvoxamine. B) The CYP1A2 inhibitor fluvoxamine increases leflunomide-induced reporter gene activity in Hepa1.1 cells. Hepa1.1 cells were pre-treated with fluvoxamine for 3 hours and then dosed with 0.5 µM leflunomide for an additional 4 hours. Leflunomide-mediated reporter gene activity was enhanced by pre-treatment with fluvoxamine compared with vehicle treated cells and fluvoxamine-only treated cells. Results are the mean ± SEM of three independent experiments, each with at least three biological replicates. * p<0.05 relative to vehicle treatment, ** p<0.001 relative to both vehicle treatment and vehicle treated cells pre-treated with fluvoxamine.CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 46 references

Cited by

See all 140

Metadata

Authors
O'Donnell, E. F., Saili, K. S., Koch, D. C., Kopparapu, P. R., Farrer, D., Bisson, W. H., Mathew, L. K., Sengupta, S., Kerkvliet, N. I., Tanguay, R. L., & Kolluri, S. K.
Affiliations
  • Oregon State University (US)
  • University of Geneva (CH)
Corresponding author
Kolluri, Siva Kumar
Venue
PLoS ONE
Published
2010-10-01
Volume
5
Issue
10
Pages
e13128
ISSN
1932-6203 (ISSN-L)
OpenAlex
W2009762618
Cited by
124
References
45
Citations by year
2026: 5 · 2025: 5 · 2024: 6 · 2023: 12 · 2022: 14 · 2021: 7 · 2020: 9 · 2019: 14 · 2018: 7 · 2017: 9 · 2016: 5 · 2015: 8 · 2014: 7 · 2013: 6 · 2012: 6
FWCI
3.62
Type
journal article
Language
en
Open access
Locations
  • PLoS ONE (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
Funders
  • National Science Foundation (0641409)
  • U.S. Department of Defense (W81XWH)
  • National Institutes of Health (1f31ca144571-01)
  • National Cancer Institute (F31 CA144571, 1F31CA144571-01)
  • National Institute of Environmental Health Sciences (ES-00-210, R01ES016651, P30ES000210, ES016651, P42ES016465, T32ES007060)
Topics
  • Physical Sciences › Environmental Science › Health, Toxicology and Mutagenesis › Toxic Organic Pollutants Impact
  • Life Sciences › Immunology and Microbiology › Immunology › Immunotoxicology and immune responses
  • Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Pharmacology › Pharmacogenetics and Drug Metabolism
Keywords
leflunomide, aryl hydrocarbon receptor, AhR agonists, A771726, pyrimidine biosynthesis inhibition, cytochrome P450 metabolism, nuclear translocation, epimorphosis, fin regeneration, zebrafish, lymphocyte proliferation, rheumatoid arthritis, anti-inflammatory agents, immune-mediated diseases
MeSH terms
Leflunomide, Animals, Anti-Inflammatory Agents, Base Sequence, Cell Line, Fluorescent Antibody Technique, Isoxazoles, Ligands, Mice, Inbred C57BL, Regeneration, Zebrafish, Polymerase Chain Reaction, Genes, Reporter, DNA Primers, Receptors, Aryl Hydrocarbon, Cytochrome P-450 CYP1A2, Mice

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: The Anti-Inflammatory Drug Leflunomide Is an Agonist of the Aryl Hydrocarbon Receptor. https://app.cochat.ai/papers/10.1371/journal.pone.0013128
The paper
O'Donnell, E. F., Saili, K. S., Koch, D. C., Kopparapu, P. R., Farrer, D., Bisson, W. H., Mathew, L. K., Sengupta, S., Kerkvliet, N. I., Tanguay, R. L., & Kolluri, S. K. (2010). The Anti-Inflammatory Drug Leflunomide Is an Agonist of the Aryl Hydrocarbon Receptor. PLoS ONE. https://doi.org/10.1371/journal.pone.0013128

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.